Zhitong Finance App News, Huiyu Pharmaceutical (688553.SH) issued an announcement. The company recently received the “Drug Registration Certificate” for the company's product lanreotide acetate sustained-release injection (prefilled) approved and issued by the State Drug Administration. The company's approved Lanreotide Acetate Sustained Release Injection (prefilled) is classified as a chemical class 4. It was reviewed and approved according to technical requirements consistent with the quality and efficacy of the reference formulation. After approval, it is treated as if it has passed the consistent evaluation of the quality and efficacy of the generic drug.

According to reports, lanreotide acetate sustained-release injection (prefilled) is a high-barrier complex sustained-release injection. Its main indications are: when growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels are abnormal in the blood after surgery and/or radiation therapy, or treatment of acromegaly where surgery and/or radiation therapy cannot be performed; it is used for adult patients with unresectable, highly differentiated or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve survival with no progression; Adult patients: When treated with this product It can reduce the frequency of emergency treatment with short-acting somatostatin analogs.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.